Progressive cell loss is observed in the striatum, cerebral cortex, thalamus, hypothalamus, subthalamic nucleus and hippocampus in Huntington disease. In the striatum, dopamine-responsive medium spiny neurons are preferentially lost. Clinical features include involuntary movements, gait and orofacial impairments in addition to cognitive deficits and psychosis, anxiety and mood disorders. We utilized the Cre-LoxP system to generate mutant mice with selective postnatal ablation of D1 dopamine receptor-expressing striatal neurons to determine which elements of the complex Huntington disease phenotype relate to loss of this neuronal subpopulation. Mutant mice had reduced body weight, locomotor slowing, reduced rearing, ataxia, a short stride length widebased erratic gait, impairment in orofacial movements and displayed haloperidol-suppressible tic-like movements. The mutation was associated with an anxiolytic profile. Mutant mice had significant striatal-specific atrophy and astrogliosis. D1-expressing cell number was reduced throughout the rostrocaudal extent of the dorsal striatum consistent with partial destruction of the striatonigral pathway. Additional striatal changes included up-regulated D2 and enkephalin mRNA, and an increased density of D2 and preproenkephalin-expressing projection neurons, and striatal neuropeptide Y and cholinergic interneurons. These data suggest that striatal D1-cell-ablation alone may account for the involuntary movements and locomotor, balance and orofacial deficits seen not only in HD but also in HD phenocopy syndromes with striatal atrophy. Therapeutic strategies would therefore need to target striatal D1 cells to ameliorate deficits especially when the clinical presentation is dominated by a bradykinetic/ ataxic phenotype with involuntary movements.
t r a c t a r t i c l e i n f o Introduction
Huntington disease (HD) is an autosomal dominant neurodegenerative disorder characterised by hyperkinetic involuntary movements, gait and orofacial abnormalities, cognitive deficits and psychiatric disturbances and death within 15-20 years. In early stages, individuals typically manifest subtle changes in motor coordination, choreiform involuntary movements and mild depression with florid chorea and cognitive impairment occurring with disease progression. In later stages, limbs become rigid, volitional movements slow and dementia occurs (Young et al., 1986) . Typically, the severity of chorea lessens while dystonia increases over time (Feigin et al., 1995) . A wide number of neurodegenerative conditions have features resembling HD but lack the causative genetic expansion. The differential diagnosis of such HD phenocopy syndromes has been reviewed (Wild and Tabrizi, 2007) . Striatal degeneration and an akinetic rigid-presentation akin to the juvenile HD Westphal variant are seen in some HD phenocopy syndromes such as Huntington disease-like syndrome 2 (Wild and Tabrizi, 2007) .
The striatum is densely innervated with dopaminergic projections and consists of a high density of postsynaptic D1 dopamine receptor (abbreviated Drd1a for rodents)-and D2 receptor (Drd2)-expressing medium spiny neurons (MSN) (Yung et al., 1995) . Substantia nigra
